AC Immune (ACIU) Accumulated Depreciation (2016 - 2017)
AC Immune (ACIU) posted quarterly Accumulated Depreciation of -$2.7 million for Q3 2017, down 23.22% quarter-over-quarter from -$2.2 million in Q4 2016.
AC Immune (ACIU) Accumulated Depreciation (2016 - 2017) Analysis & Trends
AC Immune (ACIU) has reported Accumulated Depreciation for 2 consecutive years, with -$2.7 million the latest figure, recorded in Q3 2017.
- In Q3 2017, Accumulated Depreciation changed N/A year-over-year to -$2.7 million; the TTM figure through Sep 2017 stood at -$2.7 million (changed N/A YoY), while the FY2016 annual figure was -$2.2 million, changed N/A from the prior year.
- Accumulated Depreciation retreated to -$2.7 million in Q3 2017 per ACIU's latest filing, from -$2.2 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at -$2.2 million in Q4 2016 and bottomed at -$2.7 million in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | -2.66 Mn |
| Dec 31, 2016 | -2.16 Mn |